GLP-1 Receptor Agonists Linked to Lower Dementia Risk in Type 2 Diabetes

GLP-1 receptor agonists linked to lower dementia risk in type 2 diabetes

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access journal BMJ Open Diabetes Research & Care.

Risk for dementia, ischemic stroke, mortality lower with GLP-1 receptor agonists in type 2 diabetes, obesity

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs, according to a study published online July 15 in JAMA Network Open.

GLP-1 Receptor Agonists Linked to Lower Dementia Risk Than Metformin in Type 2 Diabetes Study

A recent study suggests that GLP-1 receptor agonists, a […] The post GLP-1 Receptor Agonists Linked to Lower Dementia Risk Than Metformin in Type 2 Diabetes Study first appeared on GeneOnline News. The post GLP-1 Receptor Agonists Linked to Lower Dementia Risk Than Metformin in Type 2 Diabetes Study appeared first on GeneOnline News.

expert reaction to observational study of GLP-1 receptor agonists and metformin in people with type 2 diabetes and risk of dementia

An observational study published in BMJ Open Diabetes Research & Care looks at GLP-1 drugs vs metformin and the risk of dementia in people with type 2 diabetes.    Dr Richard Oakley, Associate Director of Research and Innovation, Alzheimer’s Society, said:  “Dementia is the UK’s biggest killer and one in three people born today will go onto to develop the condition. So, it’s exciting to see more research which shows how drugs currently being use…

Study shows Semaglutide May Help Lower Dementia Risk

A massive new study involving 1.7 million patients has determined that the risk of dementia drops significantly for those taking semaglutide—the active ingredient used in weight loss drugs like Ozempic and Wegovy. Since it’s approval for medical use in the U.S. less than ten years ago, doctors have been keen to learn more about the effects of semaglutide beyond it’s proven ability to reduce appetite and help people to drop significant amounts of…

GLP-1 Agonists Linked to Lower Dementia and Stroke Risk in Diabetes

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.